Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug
Authors
Keywords
-
Journal
Gastroenterology Research and Practice
Volume 2015, Issue -, Pages 1-9
Publisher
Hindawi Limited
Online
2015-01-22
DOI
10.1155/2015/456895
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Myocarditis due to mesalamine treatment in a patient with Crohn’s disease in China
- (2016) Yangyang LIU et al. Turkish Journal of Gastroenterology
- Current issues in inflammatory bowel disease neoplasia
- (2015) Michael Vieth et al. HISTOPATHOLOGY
- Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine
- (2014) Leo Russo et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- High- and Low-Dose Oral Delayed-Release Mesalamine in Children With Mild-to-Moderately Active Ulcerative Colitis
- (2014) Harland S. Winter et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- IBD—genes, bacteria and new therapeutic strategies
- (2014) Jean-Frederic Colombel Nature Reviews Gastroenterology & Hepatology
- 5-Aminosalicylates Reduce the Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis: An Updated Meta-Analysis
- (2014) Li-Na Zhao et al. PLoS One
- Modulation of N-glycosylation by mesalamine facilitates membranous E-cadherin expression in colon epithelial cells
- (2013) Vineeta Khare et al. BIOCHEMICAL PHARMACOLOGY
- 5-ASA Induced Recurrent Myopericarditis and Cardiac Tamponade in a Patient with Ulcerative Colitis
- (2013) Irene Sonu et al. DIGESTIVE DISEASES AND SCIENCES
- Pure white cell aplasia induced by mesalazine in a patient with ulcerative colitis
- (2013) Francesco Frattini et al. Hematology
- Antioxidant Properties of Mesalamine in Colitis Inhibit Phosphoinositide 3-Kinase Signaling in Progenitor Cells
- (2013) Elizabeth Managlia et al. INFLAMMATORY BOWEL DISEASES
- Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews
- (2013) Brian G. Feagan et al. INFLAMMATORY BOWEL DISEASES
- Peripheral T-cell lymphoma mimicking 5-aminosalicylate hypersensitivity in ulcerative colitis
- (2013) L. M. Kong et al. INTERNAL MEDICINE JOURNAL
- Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Mesalazine in the Chemoprevention of Colorectal Cancer
- (2013) Carmine Stolfi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Acute pleuropericarditis in a patient with primary Sjögren's syndrome and quiescent ulcerative colitis in longstanding 5-aminosalicylic acid therapy
- (2013) Rami Qanneta et al. Journal of Crohns & Colitis
- A Curious Case of Red-Brown Urine in a Child Taking Mesalamine
- (2013) Alan Sacks et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Mesalamine-induced myocarditis following diagnosis of Crohn's disease: A case report
- (2013) Carlos Galvão Braga et al. Revista Portuguesa de Cardiologia
- 5-Aminosalicylic Acid Is Not Protective Against Colorectal Cancer in Inflammatory Bowel Disease: A Meta-Analysis of Non-Referral Populations
- (2012) Geoffrey C Nguyen et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1
- (2012) Vineeta Khare et al. BIOCHEMICAL PHARMACOLOGY
- Role of β2-adrenoceptor-β-arrestin2-nuclear factor-κB signal transduction pathway and intervention effects of oxymatrine in ulcerative colitis
- (2012) Heng Fan et al. Chinese Journal of Integrative Medicine
- Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus
- (2012) Peter A Banks et al. GUT
- Recurrence of Myocarditis After Mesalazine Treatment for Ulcerative Colitis
- (2012) Tony Sabatini et al. INFLAMMATORY BOWEL DISEASES
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
- (2012) Axel Dignass et al. Journal of Crohns & Colitis
- 5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: A nationwide survey
- (2012) Camille Zallot et al. Journal of Crohns & Colitis
- Mesalamine in the treatment and maintenance of remission of ulcerative colitis
- (2012) Maggie Ham et al. Expert Review of Clinical Pharmacology
- Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis
- (2011) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis
- (2011) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Recurrent myopericarditis with extensive ulcerative colitis
- (2011) Hugh James Freeman et al. CANADIAN JOURNAL OF CARDIOLOGY
- Conventional Medical Management of Inflammatory Bowel Disease
- (2011) Daniel Burger et al. GASTROENTEROLOGY
- Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
- (2011) Natalie A. Molodecky et al. GASTROENTEROLOGY
- Phenotyping with sulfasalazine – time dependence and relation to NAT2 pharmacogenetics
- (2011) U.D. Kuhn et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents
- (2010) Melvin B. Heyman et al. INFLAMMATORY BOWEL DISEASES
- Systematic Review of the Evidence Base for the Medical Treatment of Paediatric Inflammatory Bowel Disease
- (2010) DC Wilson et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine
- (2009) A. LYAKHOVICH et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Mesalazine inhibits theβ-catenin signalling pathway acting through the upregulation of μ-protocadherin gene in colo-rectal cancer cells
- (2009) S. PARENTI et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Myocarditis by mesalazine with cardiac magnetic resonance imaging
- (2009) Luis García-Ferrer et al. EUROPEAN HEART JOURNAL
- Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis
- (2009) William J. Sandborn et al. GASTROENTEROLOGY
- Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis - methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa
- (2008) G. R. LICHTENSTEIN et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Mesalamine-Associated Hypersensitivity Myocarditis in Ulcerative Colitis
- (2008) Sundae Stelts et al. ANNALS OF PHARMACOTHERAPY
- PPAR is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells
- (2008) M. Schwab et al. CARCINOGENESIS
- The many faces of PPARγ: Anti-inflammatory by any means?
- (2008) Attila Szanto et al. IMMUNOBIOLOGY
- 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis
- (2008) Margie L. Clapper et al. INFLAMMATORY BOWEL DISEASES
- Molecular basis of the potential of mesalazine to prevent colorectal cancer
- (2008) Carmine Stolfi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- NAT1 Genotypes Do not Predict Response to Mesalamine in Patients with Ulcerative Colitis
- (2008) M Hausmann et al. ZEITSCHRIFT FUR GASTROENTEROLOGIE
- Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid
- (2007) Carmine Stolfi et al. BIOCHEMICAL PHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now